Three patents were granted by the US Patent office, which served as validation and recognition of the successful work and research of Dr. Diehl. The first was granted in 1977, and was granted for cetyl myristoleate, as follows:
U.S. Patent #4049824, September 20, 1977, Cetyl Myristoleate
In 1978, Dr. Diehl was granted a patent for the actual treatment of Rheumatoid Arthritis (RA):
U.S. Patent #4113881, September 12, 1978, Method of Treating Rheumatoid Arthritis
And finally, in 1996, Dr. Diehl was granted another patent, this time for the treatment of OsteoArthritis:
U.S. Patent #5569676, October 29, 1996, Method for the Treatment of Osteoarthritis
The results of Mr. Diehl’s work and patents was confirmed and published in the prestigious Trade Journal, Pharmaceutical Sciences 1994; Issue/Vol 83: pages 296-9.
By comparison, neither Glucosamine, Chondroitin, MSM, Hyaluronic Acid, Curcurmin, Resveratrol, nor any other natural remedy holds an actual US patent based on its ability to treat arthritis, joint pain, or sports related pain.
CM8 Clinical Studies
About “Independent” Research Studies
The validity of Research Studies is most often guaged by who funded the study. In many if not most cases, a product pays for a study on its own products. Such a study is not considered “independent” as the Researching Company is being paid by the product manufacturer, tainting their results. As the saying so aptly goes, ‘Money Talks”, and not the study.
CM8 was subjected to two (2) Independent, non-subsidized Studies, both of which supported and confirmed the findings of Dr. Harry Diehl.
Synopsis of Cetyl Myristoleate Study I
A more recent Cetyl Myristoleate study, performed by H. Siemandi, M.D., Ph.D., was published in the August / September 1997 issue of the Townsend Letter for Doctors & Patients. This Cetyl Myristoleate study was performed as a randomized, double blind, placebo parallel trial with 382 patients who had been diagnosed with degenerative joint disease (DJD or osteoarthritis), rheumatoid arthritis, and psoriatic arthritis. This group was divided into three groups for testing. The first Group A received a complex of fatty acids (90 grams) containing 12% Cetyl Myristoleate, the second Group B received the same complex of CM fatty acid esters plus glucosamine hydrochloride, sea cucumber (a sea animal commonly found in the Great Barrier Reef in Australia – related to the Starfish), and hydrolyzed cartilage, and the third Group C received a placebo. Treatment consisted of a one-month protocol. Outcome measures included a variety of patient-reported, clinical, laboratory, and radiographic assessments. The results were as follows (expressed in percent improvement):
|
Group A |
Group B |
Group C |
|
|
Treatment Response |
63.3% |
87.3% |
14.5% |
|
M.D. Overall Assessment |
58.1% |
84.2% |
13.9% |
|
Patient Overall Assessment |
59.2% |
88.2% |
16.1% |
|
Joint Swelling Score |
47.5% |
77.2% |
21.1% |
(Full Text of Research Study HERE)
Synopsis of Cetyl Myristoleate Study II
A second Independent Clinical Trial, performed by the San Diego Clinic Immunological Center, entitled “Clinical Study On Cetylmyristoleate (CM8) vs Arthritis” further confirmed the findings of both Dr. Diehl and Dr. Siemandi, and quantified the dosage and conditions for successful treatment of arthritis using CM8, and identifying conditions which might inhibit its effectiveness. The complete results of this Independent Clinical Research Trial in their entirety can also be found on the Harry Diehl website, and was